Provides candidate imaging biomarkers (striatal dopaminergic and hippocampal subfield asymmetry) that could aid stratification and endpoint selection for trials targeting cognitive decline in PD, though results are exploratory and sample-limited.

While not revealing therapeutic mechanisms, the technique provides a reliable, noninvasive imaging biomarker that could support patient stratification and multimodal outcome measures in clinical trials, though it is insufficient as a standalone diagnostic or severity marker.

The study underscores profound individual variability that complicates clinical trial design and patient stratification and flags BMI as a potential modifiable factor to investigate, but it offers limited direct mechanistic or therapeutic leads.

Offers a low-cost, interpretable gait-kinematic biomarker sensitive to dopaminergic state that could aid clinical monitoring or serve as an outcome measure in therapeutic trials, though small sample size and lack of mechanistic targets limit direct drug-discovery impact.

Although it does not identify therapeutic mechanisms, the paper establishes MPM as a sensitive, biologically informed noninvasive biomarker for cortical pathology and disease progression that can aid patient stratification and outcome measurement in PD therapeutic development.

This negative pilot finding reduces the likelihood that peripheral skin alpha-synuclein is a broadly useful biomarker or target in idiopathic SFN and implies peripheral synuclein pathology may be specific to systemic synucleinopathies, informing biomarker strategies and patient selection for…

While TCS has limited mechanistic or therapeutic implications, it may offer a low‑cost, scalable adjunctive biomarker to help stratify atypical parkinsonism patients in clinical studies and improve diagnostic confidence for trial enrollment.

While not identifying therapeutic targets, the work is clinically valuable for Parkinson's research because it quantifies a nontrivial rate of equivocal DAT-SPECTs that can confound diagnosis, patient selection, and biomarker endpoints in trials and thus helps improve study design and…

LRRK2 is a genetically validated PD target, so a potent, brain-penetrant, nongenotoxic inhibitor with favorable selectivity and dosing potential is a strong preclinical candidate for translation toward Parkinson's disease therapies.

Identifies a circuit-level mechanism (bursting and delta coupling) in the human STN that could serve as a biomarker or target for refining DBS/closed‑loop stimulation to improve inhibitory control and impulsivity in Parkinson's disease.

A blood-based misfolding biomarker could enable population screening and earlier patient stratification to improve Parkinson's clinical trial enrollment and timing of interventions, accelerating translational efforts despite not identifying new therapeutic targets.

Offers a noninvasive, medication‑resistant physiological biomarker of autonomic dysfunction useful for patient stratification or monitoring in trials, but provides limited mechanistic insight or immediate therapeutic targets.

It points to actionable therapeutic avenues—iron modulation, boosting antioxidant/selenoprotein pathways, and ferroptosis inhibition—that could be leveraged or repurposed in PD to protect glia, limit iron-driven toxicity, and potentially slow disease progression.

Identifies multiple actionable mechanisms (mitochondrial dysfunction, neuroinflammation, dopaminergic impairment, gut–brain axis) relevant to PD that support both lifestyle intervention and potential therapeutic or repurposing strategies, though the review is broad and not PD-specific.

Useful for Parkinson's therapeutic discovery because it highlights clinically relevant serotonergic agents (notably pimavanserin) and rational multi-target design/repurposing opportunities for symptomatic management, though it lacks new preclinical or disease‑modifying mechanisms (e.g.,…

Provides a mechanistic, druggable link between c-Abl/pY39-driven α-synuclein aggregation and iron-dependent oxidative toxicity, pointing to c-Abl inhibition, pY39-targeted aggregation blockers, or iron-modulating therapies as actionable strategies for PD.

By linking a specific, druggable protease to lysosomal degradation of α-synuclein seeds and demonstrating in vivo neuroprotective effects, the work highlights TPPII as a translationally relevant target for therapies (e.g., gene delivery or small-molecule activators) to slow or prevent Parkinson's…

This paper presents an actionable, pathology-targeting lead with biophysical and cellular evidence for fibril disassembly, making it a promising starting point for medicinal chemistry optimization and in vivo evaluation toward a potential disease-modifying Parkinson's therapy.

Points to a druggable mechanism—GSK-3β–mediated tau phosphorylation leading to ER/mitochondrial dysfunction—that links tau pathology to dopaminergic neuron loss and offers actionable targets (kinase inhibition, ER/mitochondrial protection) for developing or repurposing therapeutics for…

This work provides actionable, translational advances for adaptive deep brain stimulation—showing a practical modeling approach and choice of biomarker that can make real-time symptom-responsive neuromodulation more accurate and robust, accelerating device-level improvements even though it does not…